RSLS Insider Trading (ReShape Lifesciences)
Insider Ownership Percentage: 8.10%
Insider Buying (Last 12 Months): $158,550.00
Insider Selling (Last 12 Months): $1,776,199.35
ReShape Lifesciences Share Price & Price History
Current Price: $0.56
Price Change: ▼ Price Decrease of -0.02 (-3.45%)
As of 07/1/2022 01:00 AM ET
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
ReShape Lifesciences Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/1/2022 | Barton P. Bandy | CEO | Sell | 11,309 | $0.95 | $10,743.55 | 796,214 |  |
| 5/31/2022 | Thomas Stankovich | CFO | Buy | 20,000 | $0.92 | $18,400.00 | 365,627 | |
| 4/1/2022 | Barton P. Bandy | CEO | Sell | 11,063 | $1.13 | $12,501.19 | 818,940 | |
| 4/1/2022 | Thomas Stankovich | CFO | Sell | 5,038 | $1.13 | $5,692.94 | 350,156 | |
| 1/31/2022 | Barton P. Bandy | CEO | Sell | 8,324 | $1.22 | $10,155.28 | | |
| 1/31/2022 | Thomas Stankovich | CFO | Sell | 3,684 | $1.22 | $4,494.48 | | |
| 1/4/2022 | Barton P. Bandy | CEO | Sell | 7,150 | $1.79 | $12,798.50 | | |
| 1/4/2022 | Thomas Stankovich | CFO | Sell | 3,171 | $1.78 | $5,644.38 | | |
| 12/2/2021 | Barton P. Bandy | CEO | Sell | 13,427 | $1.83 | $24,571.41 | | |
| 12/2/2021 | Thomas Stankovich | CFO | Sell | 4,304 | $1.83 | $7,876.32 | | |
| 11/18/2021 | Thomas Stankovich | CFO | Buy | 20,000 | $2.02 | $40,400.00 | | |
| 11/2/2021 | Barton P. Bandy | CEO | Sell | 13,505 | $2.69 | $36,328.45 | | |
| 11/2/2021 | Thomas Stankovich | CFO | Sell | 4,320 | $2.69 | $11,620.80 | | |
| 10/1/2021 | Barton P. Bandy | CEO | Sell | 12,565 | $2.77 | $34,805.05 | | |
| 10/1/2021 | Thomas Stankovich | CFO | Sell | 3,660 | $2.76 | $10,101.60 | | |
| 9/10/2021 | Barton P. Bandy | CEO | Sell | 294,494 | $2.89 | $851,087.66 | 960,100 | |
| 9/10/2021 | Dan W. Gladney | Director | Sell | 200,000 | $2.99 | $598,000.00 | | |
| 9/10/2021 | Thomas Stankovich | CFO | Sell | 48,366 | $2.89 | $139,777.74 | 315,995 | |
| 8/30/2021 | Thomas Stankovich | CFO | Buy | 15,000 | $3.43 | $51,450.00 | 32,613 | |
| 8/20/2021 | Thomas Stankovich | CFO | Buy | 15,000 | $3.22 | $48,300.00 | 17,613 | |
| 12/4/2020 | Armistice Capital Master Fund | Major Shareholder | Buy | 6,400 | $4.16 | $26,624.00 | | |
| 9/22/2020 | Armistice Capital Master Fund | Major Shareholder | Buy | 3,300 | $4.13 | $13,629.00 | | |
| 8/20/2020 | Armistice Capital Master Fund | Major Shareholder | Buy | 9,998 | $3.13 | $31,293.74 | | |
| 1/29/2020 | Armistice Capital Master Fund | Major Shareholder | Buy | 3,000 | $8.00 | $24,000.00 | | |
| 12/20/2019 | Armistice Capital Master Fund | Major Shareholder | Buy | 12,048 | $5.00 | $60,240.00 | | |
| 12/16/2019 | Armistice Capital Master Fund | Major Shareholder | Buy | 3,000 | $5.50 | $16,500.00 | | |
| 12/11/2019 | Armistice Capital Master Fund | Major Shareholder | Buy | 2,523 | $5.45 | $13,750.35 | | |
| 9/17/2019 | Armistice Capital Master Fund | Major Shareholder | Buy | 396,072 | $0.05 | $19,803.60 | | |
| 8/29/2019 | Armistice Capital Master Fund | Major Shareholder | Buy | 200,000 | $0.07 | $14,000.00 | | |
| 8/8/2019 | Armistice Capital Master Fund | Major Shareholder | Buy | 350,000 | $0.07 | $24,500.00 | | |
| 7/26/2019 | Armistice Capital Master Fund | Major Shareholder | Buy | 500,000 | $0.08 | $40,000.00 | | |
The Safest Option in Trades!
From Tradewins | Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
ReShape Lifesciences Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/11/2022 | GSA Capital Partners LLP | 36,490 | $43K | 0.0% | N/A | 0.196% |  |
| 11/15/2021 | Sassicaia Capital Advisers LLC | 10,000 | $29K | 0.1% | N/A | 0.063% | |
| 8/17/2021 | Armistice Capital LLC | 816,527 | $4.08M | 0.1% | N/A | 24.447% | |
| 8/16/2021 | State Street Corp | 109,999 | $0.55M | 0.0% | N/A | 3.293% | |
| 8/13/2021 | Alpine Global Management LLC | 17,000 | $85K | 0.0% | N/A | 0.509% | |
| 8/13/2021 | Geode Capital Management LLC | 23,277 | $0.12M | 0.0% | N/A | 0.697% | |
| 8/13/2021 | Vanguard Group Inc. | 51,120 | $0.26M | 0.0% | N/A | 1.531% | |
| 11/13/2018 | Renaissance Technologies LLC | 2,287,729 | $0.10M | 0.0% | N/A | 3,812.882% | |
| 8/13/2018 | International Biotechnology Trust PLC | 52,546 | $0.12M | 0.0% | -93.3% | 0.824% | |
| 2/15/2018 | Anson Funds Management LP | 219,016 | $0.32M | 0.2% | N/A | 0.731% | |
Data available starting January 2016
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Read More on ReShape Lifesciences
Volume
93,070 shs
Average Volume
192,527 shs
Market Capitalization
$10.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of ReShape Lifesciences?
